Start Date
March 1, 2022
Primary Completion Date
August 1, 2025
Study Completion Date
August 31, 2030
Gemcitabine
Patients will receive 9.3 mg/kg 9-ING-41 twice weekly with 900 mg/m2 gemcitabine on days 1 and 8 and 75 mg/m2 docetaxel on day 8 of a 21-day cycle until disease progression or unacceptable toxicity.
9-ING-41
Patients will receive 9.3 mg/kg 9-ING-41 twice weekly with 900 mg/m2 gemcitabine on days 1 and 8 and 75 mg/m2 docetaxel on day 8 of a 21-day cycle until disease progression or unacceptable toxicity.
Docetaxel
Patients will receive 9.3 mg/kg 9-ING-41 twice weekly with 900 mg/m2 gemcitabine on days 1 and 8 and 75 mg/m2 docetaxel on day 8 of a 21-day cycle until disease progression or unacceptable toxicity.
Hasbro Children's Hospital, Providence
Lifespan Cancer Insitute, Providence
Lead Sponsor
Collaborators (1)
Actuate Therapeutics Inc.
INDUSTRY
Brown University
OTHER